New Chemotherapy Technique Carries Risks for Peritoneal Mesothelioma Patients
A new way of delivering chemotherapy drugs to the site of a peritoneal mesothelioma tumor has some unique benefits, but can also be risky. The technique, called pressurized intraperitoneal aerosol chemotherapy (PIPAC) allows doctors to “spray” a solution of chemotherapy drugs directly onto peritoneal tumors through small ports in the abdomen. The intention is to uniformly coat the tumor and help keep chemotherapy drugs in … Continue reading New Chemotherapy Technique Carries Risks for Peritoneal Mesothelioma Patients
New Biomarker Could Help Eradicate Mesothelioma Resistance to Chemotherapy
Researchers in the Netherlands have unveiled what may be a major breakthrough in the chemotherapeutic treatment of malignant mesothelioma. Malignant mesothelioma, a rare and virulent cancer caused by asbestos exposure, is notoriously resistant to standard cancer treatments, including chemotherapy. Even the only chemotherapy drug specifically approved for the treatment of mesothelioma, Alimta (pemetrexed), only works for some patients. Now, a new study published in the … Continue reading New Biomarker Could Help Eradicate Mesothelioma Resistance to Chemotherapy
New Chemotherapy Booster May Extend Mesothelioma Survival
Cancer researchers say the VEGF-inhibitor nintedanib (Ofev) extended mesothelioma survival by more than five months in patients on standard chemotherapy in a new trial. That is among the findings of a recently-published Phase II study of nintedanib as an adjunct therapy to pemetrexed (Alimta) and cisplatin for malignant pleural mesothelioma. Nintedanib Trial Details Nintedanib is currently used to treat idiopathic pulmonary fibrosis and some types … Continue reading New Chemotherapy Booster May Extend Mesothelioma Survival
New Report Reveals Disparities in Mesothelioma Treatment
A new study of mesothelioma treatment and survival in the US contains some disturbing facts about treatment trends. Among them is the fact that people over 70 are much less likely to get any treatment for malignant mesothelioma, a rare but but fast-growing malignancy that can be quickly fatal. In fact, nearly a third of mesothelioma patients receive no therapy at all. The study was … Continue reading New Report Reveals Disparities in Mesothelioma Treatment
Novel Chemotherapy Technique Appears to Boost Mesothelioma Survival
German surgeons are reporting on a potential new way to improve outcomes for people with malignant pleural mesothelioma by infusing chemotherapy drugs in an isolated area and then removing them. In an article in OncoTargets and Therapy, surgical oncologists from Burghausen, Germany say they were prompted to test the new technique after radical mesothelioma surgery “failed to translate into a definite survival advantage.” Mesothelioma Treatment Risks Although … Continue reading Novel Chemotherapy Technique Appears to Boost Mesothelioma Survival
Antibody-Drug Conjugate Fails to Stop Recurrent Pleural Mesothelioma
A new drug designed to treat recurrent malignant mesothelioma while minimizing side effects has failed to meet expectations. Anetumab ravtansine, is an antibody-drug conjugate (ADC) developed with biotechnology firms ImmunoGen and MorphoSys and owned by Bayer. It had been the focus of a Phase II clinical trial for pleural mesothelioma. The trial has now been stopped. Understanding ADCs Many of the most dangerous side effects of … Continue reading Antibody-Drug Conjugate Fails to Stop Recurrent Pleural Mesothelioma
Study to Test New Three-Drug Treatment for Pleural Mesothelioma
The makers of a VEGF-inhibitor called nintedanib are recruiting patients with unresectable pleural mesothelioma for a Phase III clinical trial of the drug in combination with standard chemotherapy. The multicenter trial sponsored by drug maker Boehringer Ingelheim will eventually include a total of 450 mesothelioma patients, but preliminary results from the first 87 patients look promising. According to data presented at the 2017 American Society of Clinical Oncology … Continue reading Study to Test New Three-Drug Treatment for Pleural Mesothelioma
Compound in Broccoli May Enhance Mesothelioma Treatment with Cisplatin
There is new evidence that a compound found in cruciferous vegetables like broccoli and cabbage may enhance the anticancer benefits of the platinum-based drug cisplatin in the treatment of pleural mesothelioma. Although malignant mesothelioma is highly resistant to conventional cancer treatments, most mesothelioma patients will receive chemotherapy with cisplatin and pemetrexed (Alimta) as part of a multi-modal approach to treatment. Now, researchers Yoon-Jin and Sang-Han … Continue reading Compound in Broccoli May Enhance Mesothelioma Treatment with Cisplatin
Boosting Mesothelioma Survival with VEGF-Inhibitor
The VEGF inhibitor cediranib may not yet be out of the running as a mesothelioma treatment. Although previous studies have found it to have dose-limiting side effects, a new study in the Journal of Thoracic Oncology finds that, at the right dose, it could boost the effectiveness of standard mesothelioma chemotherapy. What is Cediranib? Cediranib, an oral drug made by Astra Zeneca, is a powerful … Continue reading Boosting Mesothelioma Survival with VEGF-Inhibitor
Standardization Needed for Peritoneal Mesothelioma Treatment
Mesothelioma researchers in Belgium and the US have some good news and some bad news about peritoneal mesothelioma treatment. The good news is that the combination of cytoreductive surgery to remove the mesothelioma tumor and intraperitoneal chemotherapy (HIPEC) to kill residual cancer cells improves mesothelioma survival. Overall, the method is so effective that the authors say the combination should now be considered standard of care … Continue reading Standardization Needed for Peritoneal Mesothelioma Treatment
“My Name is Paul Kraus and I Have Survived Mesothelioma for Over 20 Years.”
In 1997 I was diagnosed with mesothelioma. The doctors gave me just a few short months to live...
But here I am, 20 years later, alive and well.
I wrote a book explaining how I became the longest living mesothelioma survivor in the world.
Today, I'd like to give you a copy for free because I want more people to survive this disease.
All you have to do is click the button below now. You will receive the book within 72 hours.
I wish you good health.
Sincerely,
"It has been over four years now and I can honestly say I am doing great. I highly recommend this book because it is inspirational and educational."
Get your free copy of
“Surviving Mesothelioma” Today!